Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in Type2 diabetes

Diabetic Medicine

Volumn 28, Issue 10, 2011, Pages 1201-1205

  Natarajan, A ^a,b   Marshall, S M ^b   Kesteven, P J ^c   Mccomb, J M ^c   Rutter, M K ^d,e  

^a NHS Foundation Trust   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Acute cerebral infarction; Acute myocardial infarction; Epidemiology; Risk factors; Type2 diabetes

Indexed keywords

BLOOD CLOTTING FACTOR 12A; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN ANTITHROMBIN III COMPLEX; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; E-SELECTIN; ENDOTHELIUM, VASCULAR; FACTOR XIIA; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 80052976633     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03311.x     Document Type: Article

References (26)

1. Rutter MK, McComb JM, Brady S, Marshall SM. Silent myocardial ischemia and microalbuminuria in asymptomatic subjects with non-insulin-dependent diabetes mellitus. Am J Cardiol 1999; 83: 27-31.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
3. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F et al. Incidence of coronary heart disease in type2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 2007; 30: 1241-1247.
4. Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM et al. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes 1998; 47: 1786-1792.
5. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-4225.
6. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358: 971-976.
7. Menown IB, Mathew TP, Gracey HM, Nesbitt GS, Murray P, Young IS et al. Prediction of recurrent events by D-dimer and inflammatory markers in patients with normal cardiac TroponinI (PREDICT) Study. Am Heart J 2003; 145: 986-992.
8. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-1342.
9. Taubert G, Winkelmann BR, Schleiffer T, Marz W, Winkler R, Gok R et al. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J 2003; 145: 285-291.
10. Matsumoto K, Fujishima K, Moriuchi A, Saishoji H, Ueki Y. Soluble adhesion molecule E-selectin predicts cardiovascular events in Japanese patients with type2 diabetes mellitus. Metabolism 2010; 59: 320-324.
11. Costacou T, Lopes-Virella MF, Zgibor JC, Virella G, Otvos J, Walsh M et al. Markers of endothelial dysfunction in the prediction of coronary artery disease in type1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications 2005; 19: 183-193.
12. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006; 368: 33-47.
13. Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, Miyake S. Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med 2002; 19: 822-826.
14. Boulbou MS, Koukoulis GN, Vasiou KG, Petinaki EA, Gourgoulianis KI, Fezoulidis IB. Increased soluble E-selectin levels in type2 diabetic patients with peripheral arterial disease. Int Angiol 2004; 23: 18-24.
15. Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factorXII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 2103-2106.
16. Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE et al. Epidemiological and genetic associations of activated factorXII concentration with factorVII activity, fibrinopeptideA concentration, and risk of coronary heart disease in men. Circulation 2000; 102: 2058-2062.
17. Grundt H, Nilsen DW, Hetland O, Valente E, Fagertun HE. Activated factor12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 2004; 147: 260-266.
18. Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated FXII in survivors of myocardial infarction-association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998; 79: 14-18.
19. Bach J, Endler G, Mannhalter C, Hellstern P. Coagulation factorXII activity, activated factorXII, distribution of factorXII C46T gene polymorphism and coronary risk: reply to a rebuttal. J Thromb Haemost 2008; 6: 291-296.
20. Lowe GD, Rumley A, McMahon AD, Ford I, O'Reilly DS, Packard CJ. Interleukin-6, fibrin D-dimer, and coagulation factorsVII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529-1534.
21. Colhoun HM, Zito F, Norman Chan N, Rubens MB, Fuller JH, Humphries SE. Activated factorXII levels and factorXII 46C>T genotype in relation to coronary artery calcification in patients with type1 diabetes and healthy subjects. Atherosclerosis 2002; 163: 363-369.
22. Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factorXII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 2103-2106.
23. Ishii K, Oguchi S, Murata M, Mitsuyoshi Y, Takeshita E, Ito D et al. Activated factorXII levels are dependent on factorXII 46C/T genotypes and factorXII zymogen levels, and are associated with vascular risk factors in patients and healthy subjects. Blood Coagul Fibrinolysis 2000; 11: 277-284.
24. Asakawa H, Tokunaga K, Kawakami F. Comparison of risk factors of macrovascular complications. Peripheral vascular disease, cerebral vascular disease, and coronary heart disease in Japanese type2 diabetes mellitus patients. J Diabetes Complications 2000; 14: 307-313.
25. Morishita E, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I et al. Hypercoagulability and high lipoprotein(a) levels in patients with typeII diabetes mellitus. Atherosclerosis 1996; 120: 7-14.
26. Bosnyak Z, Forrest KY, Maser RE, Becker D, Orchard TJ. Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabet Med 2003; 20: 147-151.